Clinical and Laboratory Investigations
Unraveling the Patterns of Subclinical Pheomelanin-Enriched Facial Hyperpigmentation: Effect of Depigmenting AgentsHermanns J.F.a · Petit L.a · Martalo O.a · Piérard-Franchimont C.a · Cauwenbergh G.b · Piérard G.E.a
aUnit of Dermocosmetology, Department of Dermatopathology, University Medical Center of Liège, Belgium; bSkin Research Center, Johnson & Johnson, Skillman, N.J., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: During photoaging, the density of melanin chromatophores is heterogeneous in the epidermis. Aims: To define the patterns of pheomelanin-enriched melanotic hypermelanosis of the face in phototype II subjects and to assess the effect of depigmenting agents. Azelaic acid and glycolic acid were tested as well as a soy extract, reported to reduce pigmentation through interaction with the protease-activated receptor 2 (PAR-2) of keratinocytes. Method: Evaluations were made by image analysis of high magnification pictures obtained by a video camera equipped with an internal ultraviolet-emitting unit (Visioscan®). Results: Three patterns of subclinical facial hypermelanosis were recognized including the spotty perifollicular type, the accretive globular type and the elongated type of the sunny side of wrinkles. Azelaic acid and the soy extract led to significant skin lightening after a 3-week treatment. By contrast, glycolic acid showed an inconsistent effect. Conclusion: Sensitive fluorescence video recording combined with image analysis represents an advance in the noninvasive assessment of the mottled subclinical skin pigmentation. The depigmenting effect observed with the soy extract indicates that the inhibition of PAR-2 may be a novel way to approach certain pigmentary disorders of the skin.
© 2000 S. Karger AG, Basel
Piérard GE, Piérard-Franchimont C, Laso Dosal F, Ben Mosbah T, Arrese Estrada J, Rurangirwa A, Dowlati A, Vardar M: Pigmentary changes in skin senescence. J Appl Cosmetol 1991;9:67–63.
- Nikkels A, Ben Mosbah T, Piérard-Franchimont C, de la Brassinne M, Piérard GE: Comparative morphometry study of eruptive PUVA-induced and chronic sun-induced lentigines of the skin. Anal Quant Cytol Histol 1991;13:23–26.
- Kikuchi I, Idermori M, Uchimura H, Inoue S: Reflection ultraviolet photography as surface photography of the skin. J Dermatol 1983;10:551–555.
Arai S: Analysis of pigmentation of human skin (UV-light images); in Wilhelm KP, Elsner P, Berardesca E, Maibach HI (eds): Bioengineering of the Skin: Skin Surface Imaging and Analysis. Boca Raton, CRC Press, 1997, pp 85–94.
- Fulton JE: Utilizing the ultraviolet (UV detect) camera to enhance the appearance of photodamage and other skin conditions. Dermatol Surg 1997;23:163–169.
- Kollias N, Gillies R, Cohén-Goihman C, Phillips SB, Muccini JA, Stiller M, Drake LA: Fluorescence photography in the evaluation of hyperpigmentation in photodamaged skin. J Am Acad Dermatol 1997;36:226–230.
Piérard-Franchimont C, Piérard GE: Héliodermie hétérochrome et risque de cancers cutanés. Rev Méd Liège 1998;53:355–356.
- Nystedt S, Emilsson K, Wahlestedt C, Sundelin J: Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 1994;91:9208–9212.
- Nystedt S, Larsson AK, Aberg H, Sundelin J: The mouse proteinase-activated receptor-2 cDNA and gene: Molecular cloning and functional expression. J Biol Chem 1995;270:5950–5955.
- Seiberg M, Paine C, Sharlow E, Andrade-Gordon P, Costanzo M, Eisinger M, Shapiro S: The protease-activated receptor-2 regulates pigmentation via keratinocyte-melanocyte interactions. Exp Cell Res 2000;254:25–32.
Seiberg M, Paine C, Sharlow E, Andrade-Gordon P, Costanzo M, Eisinger M, Shapiron S: Inhibition of melanosome transfer results in skin lightening. J Invest Dermatol, in press.
Sharlow ER, Paine CS, Babiarz L, Eisinger M, Shapiro S, Seiberg M: The protease activated receptor-2 upregulates keratinocyte phagocytosis. J Invest Dermatol, in press.
Déry O, Corvera CU, Steinhoff M, Bunnett NW: Proteinase-activated receptors: Novel mechanisms of signaling by serine proteases. Am J Physiol 1998;247:C1429–C1452.
- Piérard GE: EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol 1998;10:1–11.
- Leffell DJ, Stetz ML, Milstone LM, Deckelbaum LI: In vivo fluorescence of human skin: A potential marker of photoaging. Arch Dermatol 1988;124:1514–1518.
- Takema Y, Yorimoto Y, Ohsu H, Osanai O, Kawai M: Age-related discontinuous changes in the in vivo fluorescence of human facial skin. J Dermatol Sci 1997;15:55–58.
Prota G: Melanins, melanogenesis and skin photoprotection. Eur J Cancer 1994;30A:553–554.
Thody AJ, Higgins EM, Burchill SA, Marks JM, Ito S: Epidermal eumelanin and phaeomelanin concentrations in different skin types and in response to PUVA. Br J Dermatol 1990;122:288–289.
Ortonne JP, Prota G: Hair melanins and hair color: Ultrastructural and biochemical aspects. J Invest Dermatol 1993;101:S82–S89.
Dooley TP: Topical skin depigmentation agents: Current products and discovery of novel inhibitor of melanogenesis. J Dermatol Treat 1997;8:275–279.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.